Imcivree Prescribing & Dosing Schedule

Dosage & Administration Drug label Prior authorization Pharmacy Financial assistance Patient education People also ask

Imcivree(setmelanotide)

IMCIVREE 10 MG/ML Injectable Solution

NO BOXED WARNING

Dosage & Administration

* Select patients for treatment who have genetically determined or suspected deficiency of POMC, PCSK1, or LEPR, or who have a clinical diagnosis of BBS.
* Treat patients with variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS) in the clinical context of the patient.
* Recommended starting dosage injected subcutaneously for:
* Adults and pediatric patients aged 12 years and older is 2 mg (0.2 mL) once daily for two weeks.
* Pediatric patients aged 6 to less than 12 years is 1 mg (0.1 mL) once daily for two weeks.

* Recommended target dosage for adults and pediatric patients aged 6 years and older is 3 mg (0.3 mL) injected subcutaneously once daily.
* For recommended dosage in patients with renal impairment, see Full Prescribing Information.
* For titration and administration recommendations, see Full Prescribing Information.
* Evaluate weight loss after 12-16 weeks of treatment in patients with POMC-, PCSK1-, or LEPR-deficiency or after 1 year in patients with BBS. See Full Prescribing Information for monitoring and discontinuation recommendations based on weight loss.

drug label

Imcivree Prescribing Information

Contact Medical Science Liaison

Report Adverse Event

prior authorization

Imcivree Prior Authorization Resources

Most recent state uniform prior authorization forms

Verified: Jul 26, 2024Arizona - Uniform Prior Authorization Form

Verified: Jul 26, 2024Colorado - Uniform Prior Authorization Form

Verified: Jul 26, 2024Hawaii - Uniform Prior Authorization Form

Verified: Jul 26, 2024Illinois - Uniform Prior Authorization Form

Verified: Jul 26, 2024Indiana - Uniform Prior Authorization Form

Verified: Jul 26, 2024Louisiana - Uniform Prior Authorization Form

Verified: Jul 26, 2024Minnesota - Uniform Prior Authorization Form

Verified: Jul 26, 2024New Hampshire - Uniform Prior Authorization Form

Verified: Jul 26, 2024New Mexico - Uniform Prior Authorization Form

Verified: Jul 26, 2024Oregon - Uniform Prior Authorization Form

Verified: Jul 26, 2024Texas - Uniform Prior Authorization Form

Verified: Jul 07, 2024Washington - Uniform Prior Authorization Form

Verified: Jul 07, 2024Wisconsin - Uniform Prior Authorization Form

Benefits investigation

Imcivree Start Form

pharmacy

Imcivree Preferred Pharmacy

Pharmacy List

financial assistance

Imcivree Financial Assistance Options

Copay savings program

Imcivree Start Form

Enroll in Patient Savings Program

Learn More

Overview

Reduce patient OOP costs for drug (and occasionally for drug administration/infusion costs or drug-related test costs)

Patient benefit

A portion (or all) of patient OOP (deductible, copay), typically up to monthly and/or annual max

Patient eligibility

Patient must enroll or activate (may permit HCPs to enroll on patient’s behalf for HCP-administered drugs)
Generally, must have commercial insurance (rarely, may permit uninsured patients to use)
May never be used with government insurance

How to sign up

Cards may be downloadable digital cards or hard copies
Some pharmacos offer debit cards with pre-loaded copay benefit
Typically, available through multiple channels (e.g., rep to HCP to patient; pharmacy to patient; patient via website, Hub live agent, or copay vendor (live agent or IVR); patient and HCP via Hub enrollment form)
Some HCP-administered product programs permit HCPs to enroll on a patient’s behalf through via Hub form